Computationally efficient substrate noise coupling estimation in lightly doped silicon substrates

A Z-parameter based macromodel for characterizing the substrate noise coupling in a lightly doped substrate at low frequencies has been developed. The model is scalable with contact geometries and separation. The cross-coupling impedance between two contacts is modeled using an improved geometric mean distance formulation. This approach obviates the need for using several spacing related parameters for describing the contact separations, sizes, and orientation. An improved self-impedance model has also been developed. Proximity effects of neighboring contacts are taken into account by a paneling approach. The macromodel with paneling has been successfully used to predict the noise coupling for multi-contact examples. The errors from the macromodel relative to a numerical simulator are within acceptable limits of 15%

Postoperative acute parotitis after cesarean delivery under spinal anaesthesia: a rare entity

Postoperative acute painless parotid gland swelling, which is a rare complication has been reported after caesarian section (CS) under neuraxial anaesthesia. Here, we present a parturient who suffered from acute parotitis, which developed after elective repeat CS under spinal anaesthesia.

Copepod Abundance and Diversity from Offshore Region of Tuticorin, South East Coast of India

A detailed study had been carried out on species abundance, biomass and composition of copepod in four different offshore stations namely, Station I: Vembar, II: Keelavaipar, III: Punnaikayal and IV: Thiruchendhur in Gulf of Mannar region from October 2011 to April 2012. A total of 56 copepod species belongs to 20 families under 4 orders have been encountered during the period. The percentage composition of different groups of copepod species was composed of Calanoida (35 numbers) 62.5%, Cyclopoida (4 numbers) 7.14%, Harpacticoida (8 numbers) 14.3% and Poecilostomatoida (9 numbers) 16.1%. The percentage of biomass composition of different groups of copepods during the study was in the order of Calanoida 38.99%, Harpacticoida 32.56%, Cyclopoida 15.22% and Poecilostomatoida 13.23%. In the case of species composition, Euterpina acutifrons (28.61%) was the most abundant species followed by Acrocalanus gracilis (17.68%), Corycaeus crassiusculus (12.33%), Oithona brevicornis (12.03%) and Temora turbinata (4.25%) were the other dominant species in observation. The copepod density in different stations were in the range of 8600–39900, 3900–64600, 3800–24800 and 5000–22500 numbers m-3 at station I, II, II and IV respectively. The lowest biomass of copepod was observed at station III and highest biomass was found at station II. The copepod species richness ranged from 0.48 to 2.72 and species diversity was in the range of 0.87 to 1.98 in the study areas. Species evenness was varied from 0.24 – 0.51 during the observation period

Federated Learning Framework for IID and Non-IID datasets of Medical Images

Advances have been made in the field of Machine Learning showing that it is an effective tool that can be used for solving real world problems. This success is hugely attributed to the availability of accessible data which is not the case for many fields such as healthcare, a primary reason being the issue of privacy. Federated Learning (FL) is a technique that can be used to overcome the limitation of availability of data at a central location and allows for training machine learning models on private data or data that cannot be directly accessed. It allows the use of data to be decoupled from the governance (or control) over data. In this paper, we present an easy-to-use framework that provides a complete pipeline to let researchers and end users train any model on image data from various sources in a federated manner. We also show a comparison in results between models trained in a federated fashion and models trained in a centralized fashion for Independent and Identically Distributed (IID) and non IID datasets. The Intracranial Brain Hemorrhage dataset and the Pneumonia Detection dataset provided by the Radiological Society of North America (RSNA) are used for validating the FL framework and comparative analysis

ULTRASONOGRAPHIC AND HISOPATHOLOGICAL CHANGES IN DOGS WITH CHRONIC RENAL DISEASE

ABSTRAC

Gender differences in virologic response after antiretroviral therapy in treatment-naïve HIV-infected individuals: Results from the 550 clinic HIV cohort study.

Background Controversy still exists regarding gender differences in virologic response between treatment-na•ve HIV-infected individuals. The objective of this study was to evaluate gender difference in virologic and immunologic response to antiretroviral therapy in treatment-na•ve HIV-infected individuals. Methods This was a retrospective, observational study of treatment-na•ve HIV-infected individuals managed at the 550 clinic who started antiretroviral therapy (ART) between January 1st, 2010 and December 31, 2015. Patients with available viral load and CD4 counts before and one year after initiating ART were included in this study. Virologic suppression was defined as \u3c 48 HIV-1 RNA copies/mL, and mmunologic recovery was defined as a CD4 count increase of at least 150 cells/mm3. Dichotomous variables were reported in number and percentages and analyzed using Chi-squared tests and Fisher’s exact (whichever was appropriate). Continuous variables were reported as median and interquartile range (IQR) and analyzed using Wilcox rank-sum tests. Multivariate analyses performed were logistic regressions with adjustment for other covariates. P value \u3c0.05 was considered statistically significant. R version 3.3.2 was used for the statistical analysis. Results A total of 70 women and 90 men were included in the study. Median age was 41 years (19) for women and 34 years (19) for men (P \u3c 0.001). Virologic suppression was documented in 76% of women and 64% of men (p 0.166). Immune recovery was documented in 60% of women and 68% of men (p 0.323). Multivariate analysis of virologic success is shown in Figure 1 and immunologic recovery is shown in Figure 2. Open in new tabDownload slide Open in new tabDownload slide Conclusion In our study, gender was not found to be associated with differences in response to ART. As expected, drug abuse continues to be an independent variable associated with lack of virologic suppression. If one of the goals of treatment is to achieve a rapid immunologic response, our study may indicate that regimens containing protease inhibitors should be the ones selected

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Background Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. Methods RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61–69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1–10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688–1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4–82·5) in the no ADT group and 80·4% (76·6–83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. Interpretation Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Background Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain. Methods RADICALS-HD was a randomised controlled trial of ADT duration within the RADICALS protocol. Here, we report on the comparison of short-course versus long-course ADT. Key eligibility criteria were indication for radiotherapy after previous radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to add 6 months of ADT (short-course ADT) or 24 months of ADT (long-course ADT) to radiotherapy, using subcutaneous gonadotrophin-releasing hormone analogue (monthly in the short-course ADT group and 3-monthly in the long-course ADT group), daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as metastasis arising from prostate cancer or death from any cause. The comparison had more than 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 75% to 81% (hazard ratio [HR] 0·72). Standard time-to-event analyses were used. Analyses followed intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov , NCT00541047 . Findings Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60–69) were randomly assigned to receive short-course ADT (n=761) or long-course ADT (n=762) in addition to postoperative radiotherapy at 138 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 8·9 years (7·0–10·0), 313 metastasis-free survival events were reported overall (174 in the short-course ADT group and 139 in the long-course ADT group; HR 0·773 [95% CI 0·612–0·975]; p=0·029). 10-year metastasis-free survival was 71·9% (95% CI 67·6–75·7) in the short-course ADT group and 78·1% (74·2–81·5) in the long-course ADT group. Toxicity of grade 3 or higher was reported for 105 (14%) of 753 participants in the short-course ADT group and 142 (19%) of 757 participants in the long-course ADT group (p=0·025), with no treatment-related deaths. Interpretation Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy. For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy. Funding Cancer Research UK, UK Research and Innovation (formerly Medical Research Council), and Canadian Cancer Society